Event

Alzheimer’s disease (AD) is a debilitating condition that progressively impacts patients’ cognition and independence, places significant burden on the time and well-being of caregivers, and has broad economic implications for society at large. As potential disease-modifying treatments for AD near the market, understanding the factors that influence society’s willingness and ability to pay for these treatments will be central to assessing their value. Issues with particular relevance to AD include equity and distributional fairness, the insurance value of health technologies, and the severity of AD relative to other conditions. 

This educational webinar will describe factors that affect the assessment of the clinical and economic value of medical innovations, highlight specific issues with relevance to the societal value of treatments for AD, and place these issues in the context of future health technology assessments for AD treatments. 

• Understand factors influencing our societal willingness and ability to pay for AD treatments, including equity issues, insurance value, and condition severity;
• Describe potential methods for capturing these factors in the HTA context for AD, including impacts on caregiver costs and well-being;
• Discuss the diverse stakeholder perspectives needed to evaluate novel AD treatments.

Register Here

Brought to you by: BIOGEN

Moderator:

William Herring, PhD, Senior Director, RTI Health Solutions, Research Triangle Park, NC, USA

Presenters:

Louis Garrison, PhD, Professor Emeritus, University of Washington, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Seattle, WA, USA

Charles Phelps, MBA, PhD, University Professor and Provost Emeritus, University of Rochester, Rochester, NY, USA

Anirban Basu, PhD, Professor And Director, The CHOICE Institute, University of Washington, Seattle, USA